This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

France's Economic Committee (CEPS) Authorizes Reimbursement Of Esbriet® (pirfenidone)

PARIS, Sept. 11, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the Comite Economique des Produits de Sante (CEPS) has granted reimbursement for Esbriet® (pirfenidone), making it the first medicine for the treatment of idiopathic pulmonary fibrosis (IPF) to be reimbursed in France. The price of Esbriet is expected to be published in France's Journal Officiel in the fourth quarter of 2012; the final step in the reimbursement process for a new medicine in France. 

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Professor Vincent Cottin of the National Reference Center for Rare Pulmonary Diseases said, "IPF is a devastating disease with a mortality rate similar to many cancers. Until now, French patients with IPF had no licensed therapy available to them. Esbriet is a clear step forward in the treatment of patients suffering with mild to moderate IPF as it is the first medicine to slow the progression of this disease. I am very pleased that Esbriet will soon be available in France."

The CEPS authorized an ex-factory reimbursed price of 1.923,08€ for a four-week treatment pack of Esbriet, corresponding to 25,000€ per patient, per year (approximately $32,000 USD at current exchange rates). Esbriet will be reimbursed by the French National Health Insurance system for the treatment of mild to moderate forms of IPF in adults.

Esbriet will be reimbursed as a "Medicament d'Exception," which means that it will be reimbursed only for the labeled indication, defined previously by the Commission de Transparence of the French High Health Authority (CT) as IPF patients with forced vital capacity (FVC) > 50% and carbon monoxide diffusing capacity (DLco) > 35%.  

In agreement with CEPS, InterMune France will collect information in the form of a patient registry regarding the use of Esbriet in clinical practice. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs